secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2025-06-06T23:59:59+00:00
Accession:  0000950170-25-083046
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stockholders approve Amended 2014 Plan adding 4.75M shares; annual meeting results
--------------------------------------------------------------------------------

- Stockholders approved Amended 2014 Equity Incentive Plan, increasing authorized shares by 4,750,000.
- Elected Helen Collins, M.D., Thomas Malley, and Carol Schafer as Class II directors until 2028.
- Ratified Ernst & Young as independent auditor for fiscal year ending December 31, 2025.
- Advisory vote on executive compensation approved with 63,155,796 for, 1,522,754 against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000095017025083046/0000950170-25-083046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000095017025083046/kura-20250605.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-083046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer